MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2025-09-30, ALT had -$121,869K decrease in cash & cash equivalents over the period. -$11,897K in free cash flow.

Cash Flow Overview

Change in Cash
-$121,869K
Free Cash flow
-$11,897K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
    • Proceeds from issuance of common...
    • Accounts payable
    • Stock-based compensation expense
    • Others
Negative Cash Flow Breakdown
    • Purchases of short-term investme...
    • Net loss
    • Accounts receivable
    • Others

Cash Flow
2025-09-30
2025-06-30
Net loss
-19,014 -41,721
Stock-based compensation expense
3,554 7,581
Depreciation of property and equipment
27 59
Accretion of discounts on short-term investments
196 1,117
Amortization of debt discount and costs
113 58
Loss on foreign currency exchange
-86 -30
Deferred income tax benefit
0 -681
Accounts receivable
524 -223
Prepaid expenses and other assets
8 1,895
Accounts payable
3,953 640
Accrued expenses and other liabilities
102 -2,064
Income tax and r&d incentive receivables
-10 -2,697
Net cash used in operating activities
-11,897 -36,190
Proceeds from sales and maturities of short-term investments
0 143,589
Purchases of short-term investments
149,321 47,573
Purchases of property and equipment
0 10
Net cash used in investing activities
-149,321 96,006
Payments of deferred offering costs
0 298
Proceeds from term loan
0 15,000
Payment for debt issuance costs
322 404
Proceeds from issuance of common stock in at-the-market offerings, net
39,517 72,571
Proceeds from issuance of common stock from employee stock purchase plan
121 170
Proceeds from exercises of stock options
33 8
Payments for tax withholding in share-based compensation
0 684
Net cash provided by (used in) financing activities
39,349 86,363
Net increase (decrease) in cash and cash equivalents and restricted cash
-121,869 146,179
Cash and cash equivalents at beginning of period
36,968 -
Cash and cash equivalents at end of period
61,278 -
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow

Proceeds from issuance ofcommon stock in...$39,517K Proceeds from issuance ofcommon stock from...$121K Proceeds from exercisesof stock options$33K Net cash provided by(used in) financing...$39,349K Canceled cashflow$322K Net increase(decrease) in cash and cash...-$121,869K Canceled cashflow$39,349K Accounts payable$3,953K Stock-based compensationexpense$3,554K Amortization of debt discountand costs$113K Accrued expenses andother liabilities$102K Loss on foreigncurrency exchange-$86K Depreciation of property andequipment$27K Income tax and r&dincentive receivables-$10K Payment for debtissuance costs$322K Net cash used ininvesting activities-$149,321K Net cash used inoperating activities-$11,897K Canceled cashflow$7,845K Purchases of short-terminvestments$149,321K Net loss-$19,014K Accounts receivable$524K Accretion of discounts onshort-term investments$196K Prepaid expenses andother assets$8K

Altimmune, Inc. (ALT)

Altimmune, Inc. (ALT)